title: The economics of abiraterone acetate for castration-resistant prostate cancer.
abstract: Abiraterone acetate is an oral medication that has recently been granted approval for the treatment of metastatic castration resistant prostate cancer (mCRPC) prior and/or after chemotherapy with docetaxel. In this article we assess the economics of abiraterone acetate in mCRPC. Relevant studies demonstrated that abiraterone acetate had a minimal budget impact on health plans. A relevant advantage was the cost savings due to the lack of chemotherapy-related side effects as well as the ease of administration. The results of cost/benefit comparative studies with other novel agents (i.e. cabazitaxel, enzalutamide, sipuleucel-T) are warranted as well as the close collaboration between urologists and medical oncologists.
authors.affiliation: University Department of Urology, Sismanoglio General Hospital, Athens, Greece.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Dellis
authors.forename: Athanasios G
authors.initials: AG
authors.lastname: Papatsoris
mesh_terms: D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D019057:Quality-Adjusted Life Years
chemical_list: D000730:Androstadienes; D000069501:Abiraterone Acetate